Generic cardiology drug prices: the potential benefits of the Marc Cuban cost plus drug company model
Introduction: Generic pharmaceuticals account for the majority of the $359 billion US pharmaceutical market, including for cardiology drugs. Amidst a lack of price transparency and administrative inefficiencies, generic drug prices are high, causing an undue burden on patients.Methods: We identified...
Saved in:
Main Authors: | Aparna Narendrula (Author), Jacob Lang (Author), Elias Mossialos (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An empirical study of the impact of generic drug competition on drug market prices in China
by: Chen Yina, et al.
Published: (2023) -
Companies reduce prices for HIV drugs in developing countries
by: Scott Gottlieb
Published: (2000) -
Has the increase in the availability of generic drugs lowered the price of cardiovascular drugs in South Africa?
by: Varsha Bangalee, et al.
Published: (2016) -
Has the increase in the availability of generic drugs lowered the price of cardiovascular drugs in South Africa?
by: Varsha Bangalee, et al.
Published: (2016) -
CostPlus and implications for generic imatinib
by: Kristina Jenei, et al.
Published: (2022)